中信证券股份有限公司 关于南京科思化学股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：科思股份 | | --- | --- | | 保荐代表人姓名：王风雷 | 联系电话：021-20262057 | | 保荐代表人姓名：艾华 | 联系电话：021-20262205 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次 | 0 次 | | 数 | | | 2．督导公司建立健全并有效执行规章制 | | | 度的情况 | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的 | 是 | | 制度、募集资金管理制度、内控制度、内 | | | 部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 共查询 6 次（每月 1 次） | | （2）公司募集资金项目进展是否与信息 | 是 ...

Business Strategy and Future Plans - The company's future strategy focuses on strengthening and expanding its core businesses of synthetic fragrances and cosmetic active ingredients, aiming to enhance its competitive advantages and international brand influence [3] - Sunscreen products will remain the mainstay of the business, with continued expansion in fragrance, personal care, and other functional personal care product ingredients [3] - The company plans to become a comprehensive supplier of daily chemical raw materials, leveraging its efficient R&D and industrialization capabilities [3] - In the short to medium term, the company will not engage in terminal cosmetics business but will continue to focus on personal care product ingredients [3] - The company is optimistic about the domestic market and has established partnerships with leading domestic brands, planning to continue advancing related businesses [4] Product Development and Market Performance - The company's PA product, which started production in the first half of last year, is expected to see a significant increase in sales this year [4] - Titanium dioxide product, which began trial production at the end of last year, is expected to gradually increase in volume in the second half of this year [4] - Amino acid surfactants, PO, and new P-S production lines are under construction, with a focus on market promotion and customer certification this year [4] - The company's sunscreen products have high gross and net profit margins, with significant barriers to entry for potential competitors [2] - The company has a competitive advantage in product structure, innovation, R&D capabilities, production and quality management systems, and global responsiveness [2] Cost and Pricing - The company's main raw materials include bulk and fine chemicals, with prices influenced by upstream crude oil and other bulk commodity price fluctuations [3] - In cases of significant raw material price increases, the company actively negotiates price adjustments with downstream customers, though there may be delays due to pricing cycles and market competition [3] - Raw material costs have slightly decreased compared to the third quarter of last year, but product prices are not fully synchronized with crude oil prices [5] - The company expects overall price trends to remain stable this year, given strong market demand and customer feedback [5] Sales and Distribution - For large and medium-sized terminal customers, the company primarily uses its own sales system for direct sales [5] - For geographically concentrated but smaller customers, the company relies on distributors to improve efficiency and reduce costs [5] - The two sales models complement each other and do not conflict [5] Human Resources and Organizational Development - The company places a high priority on human resources, continuously improving its talent pool and conducting multi-level talent reserves aligned with its business direction and future development strategy [4] - The company has implemented its first post-listing equity incentive plan and plans to conduct equity incentives every 2-3 years to motivate employees and focus on long-term development [4] - The company's core values emphasize innovation and continuous improvement, aiming to integrate macro concepts into daily work details [4] Industry Barriers and Competitive Landscape - The cosmetic active ingredient market is highly concentrated, with a stable supplier system and high standards for supplier certification, making it difficult for new entrants to gain significant customer resources in the short term [2] - The company has established a strong position in the international cosmetics supply chain through technological innovation and stable quality, continuously increasing its market share [3]

证券代码：300856 证券简称：科思股份 编号：2023-002 南京科思化学股份有限公司 投资者关系活动记录表 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名称及 人员姓名 南京科思化学股份有限公司 2022 年度业绩说明会采用网络远程 方式进行，面向全体投资者 时间 2023 年 5 月 25 日 15:00-17:00 地点 全景网"投资者关系互动平台"（http://ir.p5w.net） 上市公司接待人 员姓名 董事、总裁 杨军先生 董事、副总裁兼董事会秘书 曹晓如先生 独立董事 郭燏先生 财务总监 孟海斌先生 保荐代表人 王风雷先生 投资者关系活动 主要内容介绍 1、公司一季度业绩大增的因素构成，二季度能否维持高增 速？ 2023 年一季度营业收入同比增长主要系本期化妆品活性成 分产品销售量同比增长较大，净利润同比增长主要系公司 2021 年四季度以来基于原材料和海运费价格大幅上涨采取的产品价 格调整措施逐步落地，以及公司整体产能利用率的提升和新产品 产能的逐步释放等因素影响。 目前，公司生产销售正常，总体市场 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 南京科思化学股份有限公司（以下简称"公司"）《2022 年年度报 告 》 及 其 摘 要 已 于 2023 年 4 月 20 日在巨潮资讯网 （www.cninfo.com.cn）上披露。为使广大投资者更全面深入地了解 公司 2022 年度的经营情况，公司将于 2023 年 5 月 25 日（星期四） 15:00-17:00 举办 2022 年度业绩说明会。本次说明会将采用网络远 程的方式举行，投资者可登陆全景网"投资者关系互动平台" （http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事兼总裁杨军先生、独立董事 郭燏先生、财务总监孟海斌先生和董事、副总裁兼董事会秘书曹晓如 先生以及保荐代表人王风雷先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集相关问题。投资者可于 2023 年 5 月 23 日（星期二）15：00 前访问 http://ir.p5w.net/zj/，或扫描下方 二维码，进入问题征集专题页面。公司将在 ...

南京科思化学股份有限公司 投资者关系活动资料 证券代码：300856 证券简称：科思股份 编号：2023-001 南京科思化学股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------|-----------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 | | | | | □新闻发布会 □路演活动 | | | 类别 | | | | | □现场参观 | | | | 其他 线上会议 | | | | | 中金公司、中信证券、东吴证券、华泰证券、富国基金、嘉实基 | | 参与单位名称及 | | | | | | 金、鹏华基金、汇添富基金、中欧基金、中信建投资管等 280 个 | | 人员姓名 | | | | | 机构及个人参会 | | | 时间 | 2023 年 4 月 26 日 | | 地点 电话会议 上市公司接待人 员姓名 董事、董事会秘书 曹晓如 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥587,793,946.66, representing a 42.33% increase compared to ¥412,987,742.55 in the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was ¥160,229,516.90, a significant increase of 176.13% from ¥58,026,624.51 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥157,144,785.08, reflecting a 198.10% increase from ¥52,715,485.14 year-on-year[4] - Net profit attributable to shareholders grew by 176.13%, while net profit excluding non-recurring items increased by 198.10%[38] - The total comprehensive income for Q1 2023 was ¥159,302,758.76, up from ¥57,960,323.46, which is an increase of about 174.5% year-over-year[65] - The basic and diluted earnings per share for Q1 2023 were both ¥0.9463, compared to ¥0.3427 in the same quarter last year, marking an increase of approximately 176.5%[65] Operating Costs and Expenses - The total operating costs for Q1 2023 were ¥396,559,739.94, up from ¥351,684,030.22 in the same period last year[15] - Research and development expenses for Q1 2023 amounted to ¥31,263,696.98, compared to ¥14,921,949.46 in the previous year, indicating a significant increase in investment in innovation[15] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of ¥171,958,040.51, a turnaround from a negative cash flow of -¥13,952,287.97 in the same period last year[17] - The net cash flow from operating activities reached ¥171,958,040.51, a year-on-year increase of 1,332.47%[41] - The cash received from sales of goods and services was ¥541,873,945.65, compared to ¥356,970,397.61 in the previous period, indicating an increase of approximately 51.6%[51] - The cash and cash equivalents at the end of the reporting period were ¥329,229,925.89, down from ¥544,168,486.03 at the beginning of the year[12] - The cash and cash equivalents at the end of the period were ¥329,229,925.89, down from ¥544,118,274.13 at the beginning of the period[28] - The company reported a decrease in other comprehensive income, with a net amount of -¥926,758.14 for Q1 2023 compared to -¥66,301.05 in the previous year[65] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,477,888,881.18, reflecting a 9.13% increase compared to the end of the previous year[41] - The total assets increased to ¥2,477,888,881.18, up from ¥2,270,529,857.01, reflecting a growth of about 9.1% year-over-year[62] - The total liabilities amounted to ¥371,495,024.16, an increase from ¥325,073,996.38 in the previous year[30] - The non-current assets totaled ¥1,051,567,805.62, an increase from ¥939,433,440.52, reflecting a growth of approximately 11.9%[62] - The equity attributable to shareholders of the listed company was ¥2,106,393,857.02, up 8.27% from the previous year[41] Market and Strategic Initiatives - The company's operating revenue increased by 42.33% year-on-year, primarily due to a significant rise in sales volume of cosmetic active ingredient products[38] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[64] - The company has been approved to issue convertible bonds to unspecified investors, which may enhance its capital structure[11] - The company plans to issue convertible bonds to unspecified objects, which has been approved by the Shenzhen Stock Exchange's listing review committee[27] Production and Profitability - The company's gross profit margin improved by 22.78 percentage points year-on-year, supported by enhanced production capacity utilization and the gradual release of new product capacity[44] - The weighted average return on net assets was 7.91%, an increase from 3.58% in the previous year[41] Audit and Reporting - The report was not audited, which may impact the perception of the financial results presented[55]

Business Operations - The company operates independently in the daily chemical raw materials sector, with a complete supply, production, sales, and R&D chain[2]. - The company has no significant competition or unfair related transactions with shareholders, ensuring independent business operations[2]. - The company has established several wholly-owned subsidiaries, including Suqian Kesi Chemical Co., Ltd. and Anhui Shengnuobe Chemical Technology Co., Ltd.[63]. - The company is focused on the development of new chemical products, particularly in the personal care and household goods sectors, which are regulated by the FDA[63]. - The company is actively researching and developing new sunscreen agents, including AVB and OCT, which are recognized for their high absorption rates and safety[63]. Governance and Compliance - The company adheres to strict information disclosure obligations, ensuring transparency and timely communication with investors[20]. - The board of directors and management team are fully employed and compensated according to labor laws and company policies[1]. - The company has a structured approach to governance, aligning with legal and regulatory requirements without significant discrepancies[20]. - The company has a dedicated audit committee that reviews financial reports and compliance matters regularly[17]. - The company has appointed independent directors to enhance governance and oversight[7]. - The company has a supervisory board consisting of three members, ensuring compliance with legal and regulatory requirements[35]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[49]. - The company has established a structured governance framework to protect shareholder rights and ensure transparent operations[48]. Financial Performance - The company reported a strong performance in 2022, with total revenue reaching CNY 1.5 billion, representing a year-on-year growth of 15%[66]. - The net profit for the year was CNY 300 million, an increase of 20% compared to the previous year[66]. - The company achieved a total revenue of CNY 1,764.82 million in 2022, representing a year-on-year growth of 61.85%[142]. - The net profit attributable to shareholders reached CNY 388.14 million, marking a significant increase of 192.13% compared to the previous year[142]. - The gross profit margin improved to 36.66% due to price adjustments and increased production capacity utilization[142]. - Revenue from cosmetic active ingredients and raw materials accounted for 81.65% of total revenue, with a remarkable growth of 97.14% year-on-year[143]. - The synthetic fragrance segment saw a decline in revenue by 10.54%, contributing 16.36% to total revenue[143]. - The company's international market presence is strong, with 88.83% of revenue generated from overseas sales, a growth of 74.98% year-on-year[145]. Risk Management - The company faces risks from raw material price fluctuations, which could impact profitability, and has implemented measures to mitigate these risks[33]. - Currency exchange rate fluctuations pose a risk to the company's export revenues, which are primarily denominated in USD and EUR, and the company has engaged in forward foreign exchange transactions to manage this risk[34]. - Environmental protection risks are present due to waste emissions during production, and the company must comply with increasingly stringent environmental regulations[34]. - The company has implemented comprehensive safety measures to mitigate risks associated with hazardous chemicals in its production processes[41]. - The company highlighted potential risks and countermeasures in the "Future Development Outlook" section of the management discussion and analysis[57]. Research and Development - Continuous investment in R&D will be prioritized, with a focus on developing new products and processes in the cosmetic raw materials and synthetic fragrance sectors[32]. - The company is investing CNY 50 million in R&D for new technologies aimed at improving product efficacy and sustainability[66]. - The number of R&D personnel increased by 44.68% to 272 from 188 in the previous year[185]. - The company filed 20 new patent applications and obtained 31 patents during the reporting period, including 12 invention patents[157]. - The company is currently in the laboratory research phase for several new products, including enhanced sunscreen agents and physical sunscreen agents[153]. Market Strategy - The company has a clear strategy for future growth, focusing on market expansion and new product development[2]. - The company will increase market development efforts, focusing on collaboration with leading domestic cosmetic companies and exploring feasibility for establishing subsidiaries or warehouses in emerging markets[29]. - The company aims to expand its market presence through strategic partnerships and acquisitions in the chemical industry[63]. - The company is focusing on enhancing the safety of fragrance and flavor technology and prioritizing environmentally friendly production techniques[96]. - The company plans to expand its market presence by improving operational systems and increasing market supply capabilities[112]. Environmental and Social Responsibility - The company is committed to environmental and social responsibility, as outlined in its annual report[58]. - The company has obtained various environmental and safety certifications, ensuring compliance with industry regulations[116]. - The company has implemented advanced pollution treatment systems, including RTO thermal incinerators and wastewater treatment processes, to comply with stricter environmental regulations[121]. - The company has a waste incineration capacity of 5,000 tons/year for hazardous waste, significantly reducing disposal pressure and costs[121]. Future Outlook - The company has set a revenue target of CNY 1.8 billion for 2023, indicating a growth forecast of 20%[66]. - The company plans to utilize raised funds for various projects, including the construction of a daily chemical raw material project and the development of personal care products[193]. - The company aims to expand its market share by continuously exploring overseas markets and enhancing its product offerings[155]. - The company is exploring opportunities for growth in international markets, particularly in Asia and Europe[63].

关于南京科思化学股份有限公司 申请向不特定对象发行可转换公司债券的 审核问询函之回复报告 【天衡专字 (2023) 00017 号】 天衡会计师事务所 (特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询的 南京科思化学股份有限公司 审核问询函之回复报告 关于南京科思化学股份有限公司 申请向不特定对象发行可转换公司债券的 审核问询函之回复报告 天衡专字(2023)00017 号 深圳证券交易所: 贵所于 2022年 11月 9 日下发的《关于南京科思化学股份有限公司申请向不特定对象 发行可转换公司债券的审核间询函》(审核函〔2022〕020268 号)(以下简称"审核问询 函")已收悉。天衡会计师事务所(特殊普通合伙)作为科思股份的申报会计师(以下简称 "会计师"),就审核问询函中需会计师核查的相关问题进行了认真核查与落实。现将有关 情况汇报说明如下: 问题二 报告期内, 发行人境外收入分别为 98,191.57 万元、88 ...

南京科思化学股份有限公司 投资者关系活动资料 证券代码：300856 证券简称：科思股份 编号：2020-002 南京科思化学股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------| | | R | 特定对象调研 □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 南京康庄资产管理有限公司及其他个人投资者邮件调研 | | 人员姓名 | | | | 时间 | 2020 年 9 月 4 日 | | | 地点 | / | | | 上市公司接待人 员姓名 | / | | | 投资者关系活动 | | 针对邮件调研问题 ...

南京科思化学股份有限公司 投资者关系活动资料 证券代码：300856 证券简称：科思股份 编号：2020-001 南京科思化学股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------| | | R | 特定对象调研 □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | 类别 | □现场参观 | | | | □ 其他 | | | 参与单位名称及 | 安信证券 | 杜一帆、上海人寿保险 姜捷、国泰君安 赵新裕、西部证 | | 人员姓名 | 券 杨晖等投资者共计 | 140 人。 | | 时间 | 2020 年 8 月 31 日 | | | | 南京市江宁区苏源大道 | 19 号九龙湖国际企业总部园 B4 栋 1 楼 | | 地点 | 青创学院会议室 | | | 上市公司接待人 | 董事长 周旭明 | | | | 董事、 ...